Last updated: October 23, 2026
Dihydroxyaluminum aminoacetate, also called aluminum aminoacetate or aluminum glycinate, is a low-volume pharmaceutical excipient and antacid-related aluminum compound. Its commercial outlook is defined by stable demand from legacy oral gastrointestinal products, limited public pricing data, qualification barriers, and competition from more widely used aluminum hydroxide, magnesium hydroxide, calcium carbonate, alginates, and proton-pump inhibitor formulations.
No reliable public source reports standalone global revenue for dihydroxyaluminum aminoacetate. Financial analysis therefore relies on demand proxies: oral antacid consumption, excipient procurement trends, aluminum chemical costs, pharmaceutical quality requirements, and the performance of finished products that use the ingredient.
What is dihydroxyaluminum aminoacetate used for?
Dihydroxyaluminum aminoacetate is an aluminum-organic compound associated with antacid, buffering, and gastrointestinal formulations. It can be used as an active pharmaceutical ingredient in certain markets and as a formulation component or excipient in oral solid, powder, and liquid products.
| Attribute |
Description |
| Common names |
Dihydroxyaluminum aminoacetate, aluminum aminoacetate, aluminum glycinate |
| Chemical class |
Aluminum-organic amino-acid salt or complex |
| Reported CAS number |
13682-92-3 |
| Principal use areas |
Gastrointestinal products, antacid formulations, buffering systems |
| Typical dosage forms |
Tablets, powders, suspensions, oral liquids |
| Commercial position |
Specialty, low-volume pharmaceutical raw material |
| Primary demand driver |
Legacy gastrointestinal and antacid formulations |
| Main substitutes |
Aluminum hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate, alginates |
The product is not a mainstream high-volume excipient such as microcrystalline cellulose, lactose, povidone, or magnesium stearate. Its value comes from formulation functionality and customer-specific acceptance rather than broad volume consumption.
How large is the dihydroxyaluminum aminoacetate market?
A standalone market-size estimate is not publicly established. Specialty chemical suppliers typically report aluminum compounds within broader product categories, while pharmaceutical manufacturers do not disclose consumption by individual excipient.
The addressable market is likely small relative to the global pharmaceutical excipient market and substantially smaller than the markets for common antacid actives. Revenue is distributed across:
- Pharmaceutical-grade raw-material sales.
- Contract manufacturing of gastrointestinal products.
- Finished-dose antacid and digestive products.
- Regional products in markets where aluminum aminoacetate has historical regulatory acceptance.
The product’s market economics differ from those of a patented drug. Pricing depends on batch size, grade, documentation, testing, geographic delivery, and customer qualification. A small annual tonnage can support meaningful supplier revenue when the material is difficult to replace in an approved formulation.
Demand indicators
The most relevant demand indicators are:
- Sales of legacy antacid and gastrointestinal products.
- Continued use of oral solid and liquid over-the-counter products.
- Refill demand for products manufactured under established formulas.
- New registrations in markets that permit aluminum aminoacetate.
- Supplier retention by manufacturers that have completed excipient qualification.
- Availability of compliant aluminum and amino-acid raw materials.
The strongest demand is likely to come from established products rather than innovative medicines. New formulation adoption is constrained because manufacturers often prefer recognized, globally supported excipients with broad compendial and regulatory histories.
What are the main market dynamics for aluminum aminoacetate?
Legacy-product dependence
Dihydroxyaluminum aminoacetate is exposed to the decline or consolidation of older gastrointestinal products. Manufacturers may retain it for products with established safety and stability data, but new products often select aluminum hydroxide, magnesium hydroxide, calcium carbonate, or combination systems with larger supplier bases.
This creates a two-sided market. Existing demand can be sticky because changing an excipient may require stability work, comparative testing, regulatory notification, and commercial relabeling. New demand is harder to generate because the compound does not have the scale or universal recognition of mainstream antacid ingredients.
Substitution pressure
Substitution risk is material. The most direct alternatives include:
| Alternative |
Competitive advantage |
Limitation |
| Aluminum hydroxide |
Broad use, established regulatory history, large supply base |
Different neutralizing and physical properties |
| Magnesium hydroxide |
Widely recognized antacid, strong supplier availability |
Different gastrointestinal and laxative profile |
| Calcium carbonate |
Low cost and high consumer familiarity |
Formulation, calcium-load, and interaction considerations |
| Magnesium carbonate |
Flexible antacid use and established supply |
Different dissolution and sensory characteristics |
| Alginates |
Useful in reflux barriers and combination products |
Not a direct chemical substitute |
| Sodium bicarbonate |
Low-cost, rapid neutralization |
Sodium load and formulation limitations |
Substitution is not automatic. A formula change can alter pH, dissolution, sedimentation, taste, tablet hardness, suspension behavior, active compatibility, and shelf life. These technical effects protect incumbent use even when the compound has no meaningful patent barrier.
Supplier concentration and qualification
The market is likely more concentrated than the broader excipient sector. A pharmaceutical buyer may require:
- GMP manufacturing controls.
- Lot-to-lot assay consistency.
- Heavy-metal and elemental-impurity controls.
- Microbial limits appropriate to the dosage form.
- Residual-solvent and impurity documentation.
- Change-control procedures.
- Audit access.
- Stability and retest data.
- Supply continuity commitments.
The supplier that holds an approved vendor status can have an advantage disproportionate to its production volume. Qualification creates switching costs for buyers and reduces the ability of unqualified chemical suppliers to compete solely on price.
What is the financial trajectory for dihydroxyaluminum aminoacetate?
The likely financial trajectory is stable to modestly declining in mature markets, with occasional price increases caused by manufacturing, compliance, and logistics costs. A high-growth profile is unlikely without new formulation adoption or expansion into additional regulated markets.
Base-case trajectory
The base case has four characteristics:
- Flat or low-single-digit volume growth.
- Moderate nominal price inflation.
- Stable revenue from existing gastrointestinal products.
- Gradual substitution in newly developed formulations.
Revenue can remain stable even if volume declines because pharmaceutical-grade pricing reflects documentation and qualification, not only raw-material cost.
Upside scenario
An upside scenario would require one or more of the following:
- Increased demand for aluminum-based antacid combinations.
- Registration of products using aluminum aminoacetate in additional countries.
- A supply disruption affecting competing excipients.
- A manufacturer securing a major global finished-dose customer.
- New evidence supporting a formulation advantage over aluminum hydroxide or calcium carbonate.
- Expansion into specialized buffering or oral suspension applications.
Downside scenario
The main downside risks are:
- Discontinuation of legacy antacid products.
- Replacement with aluminum hydroxide or calcium carbonate.
- Regulatory tightening of aluminum exposure limits.
- Supplier failure or loss of GMP status.
- Raw-material contamination or elemental-impurity findings.
- Customers consolidating purchases with larger excipient suppliers.
- Lower-cost imports from chemical-grade producers after successful qualification.
| Scenario |
Volume outlook |
Price outlook |
Revenue outcome |
| Base case |
Flat to low decline |
Low to moderate increase |
Stable to modest growth |
| Upside case |
Low to moderate growth |
Stable or increasing |
Moderate growth |
| Downside case |
Moderate decline |
Limited pricing power |
Revenue contraction |
What FDA regulatory status applies to dihydroxyaluminum aminoacetate?
The regulatory status depends on whether the material is used as an inactive ingredient or as an active antacid ingredient.
The FDA Inactive Ingredient Database records excipient use in approved drug products and is used as a regulatory reference for inactive-ingredient precedent. An entry does not create a general approval for every route, dosage form, concentration, or product type. The sponsor remains responsible for demonstrating suitability in its formulation and complying with applicable FDA requirements (U.S. Food and Drug Administration, n.d.-a).
For active antacid use, the relevant question is whether the specific ingredient and intended claim fit an applicable OTC monograph, an approved new drug application, or another recognized regulatory pathway. FDA’s antacid monograph framework principally addresses recognized antacid actives and labeling conditions. Aluminum aminoacetate should not be treated as interchangeable with aluminum hydroxide merely because both contain aluminum.
FDA regulatory risk
The main regulatory risks are formulation-specific:
- Lack of an applicable U.S. OTC monograph pathway.
- Need for a new drug application or other regulatory justification.
- Questions over aluminum exposure.
- Elemental-impurity control under ICH Q3D.
- Inadequate characterization of a complex or salt form.
- Inconsistent nomenclature across applications and markets.
ICH Q3D requires risk-based control of elemental impurities, including aluminum where relevant to the formulation and manufacturing process (International Council for Harmonisation, 2019). This requirement can increase testing and documentation costs even when the compound has a long commercial history.
What is the Orange Book status of dihydroxyaluminum aminoacetate?
Dihydroxyaluminum aminoacetate does not have an Orange Book patent estate as an excipient. The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity associated with those products. It does not create a standalone Orange Book listing for a commonly used excipient (U.S. Food and Drug Administration, n.d.-b).
| Orange Book issue |
Assessment |
| Standalone Orange Book product |
No |
| Standalone listed excipient patent |
No |
| Paragraph IV exposure |
Not applicable to the excipient itself |
| Product-specific patent risk |
Possible if a finished drug claims a formulation or use |
| Regulatory exclusivity |
Product-specific, not inherent to the excipient |
What patents protect dihydroxyaluminum aminoacetate?
The compound itself is an older chemical entity and is unlikely to have meaningful composition-of-matter exclusivity in current commercial markets. The principal IP risks would arise from:
- A specific pharmaceutical formulation.
- A controlled-release or taste-masked dosage form.
- A suspension-stabilization system.
- A combination with another antacid or gastrointestinal active.
- A manufacturing process that produces a defined particle size or polymorphic form.
- A method of treating a specific gastrointestinal condition.
Those rights would protect a particular product or process, not ordinary manufacture and sale of the ingredient in all applications.
Method-of-use and formulation patents
Method-of-use patents may cover treatment of reflux, dyspepsia, gastritis, or acid-related symptoms using a particular combination. Formulation patents may claim ratios, excipient systems, dosage levels, suspension properties, or release profiles.
A manufacturer using the ingredient as a conventional excipient would generally face less patent exposure than a company copying a branded combination product. Freedom-to-operate analysis must still review claims in the countries where the finished product will be manufactured and sold.
Are there Paragraph IV challenges or biosimilar risks?
There is no meaningful Paragraph IV or biosimilar risk directed to dihydroxyaluminum aminoacetate itself.
Paragraph IV litigation applies to an abbreviated new drug application that challenges listed patents for a reference drug. It does not apply to a raw excipient sold independently. Any Paragraph IV risk would attach to a finished antacid or gastrointestinal product containing the ingredient.
Biosimilar risk is also not relevant. Dihydroxyaluminum aminoacetate is a small-molecule chemical material, not a biologic. Its competitive risks are generic substitution, formulation substitution, supplier qualification, and regulatory acceptance.
What manufacturing and IP barriers affect the market?
The most important barriers are operational rather than patent-based.
Manufacturing barriers
A commercially viable supplier must control:
- Aluminum source and purity.
- Amino-acid raw-material quality.
- Reaction stoichiometry.
- Moisture and drying conditions.
- Particle-size distribution.
- Bulk density and flow properties.
- Residual inorganic impurities.
- Packaging and moisture protection.
- Batch reproducibility.
These controls affect tablet compression, suspension stability, assay uniformity, dissolution, and shelf life. The final pharmaceutical customer may accept only a narrow specification, making scale-up and supplier substitution difficult.
Geographic coverage
Demand is likely fragmented across Asia-Pacific, Europe, Latin America, and selected Middle Eastern markets. Geographic coverage depends on:
- Local recognition of the ingredient.
- National pharmacopeial or regulatory treatment.
- Finished-product registration.
- Import controls.
- GMP inspection status.
- Availability of local contract manufacturers.
The United States may be less attractive for new active-antacid development if the ingredient lacks a clear OTC monograph pathway. It can still have commercial relevance as an inactive ingredient where an approved-product precedent exists.
How does aluminum aminoacetate compare with aluminum hydroxide?
Aluminum hydroxide has a substantially stronger commercial position because it has broader regulatory recognition, greater supplier depth, higher use across antacid products, and more established manufacturing infrastructure.
| Factor |
Dihydroxyaluminum aminoacetate |
Aluminum hydroxide |
| Market scale |
Specialty and limited |
Broad and established |
| Supplier depth |
Narrower |
Deeper |
| Regulatory familiarity |
Market-dependent |
Extensive |
| Substitution risk |
High in new products |
Lower |
| Qualification value |
High for incumbent suppliers |
Moderate because alternatives are available |
| Patent protection |
Generally limited |
Generally limited for the mature substance |
| Growth profile |
Stable or modest decline |
Stable, with broader application base |
The commercial case for aluminum aminoacetate depends on performance in a defined formulation, not on scale economics.
What litigation and settlement issues affect the market?
No major standalone patent-litigation pattern is associated with the excipient. Litigation exposure is more likely to arise in finished products involving:
- Generic antacid formulations.
- Combination products.
- Trade-secret disputes over manufacturing specifications.
- Supply agreements and exclusivity clauses.
- Product liability or contamination claims.
- Regulatory disputes involving labeling or active-ingredient status.
Settlement agreements involving branded gastrointestinal products could restrict generic launch timing, but those agreements would concern the finished product’s patents and regulatory applications rather than the excipient as a commodity.
What is the competitive landscape for suppliers and manufacturers?
Competition is divided into three groups:
- Pharmaceutical-grade specialty suppliers with documented GMP systems.
- Regional chemical manufacturers seeking pharmaceutical qualification.
- Contract manufacturers that purchase the material for finished gastrointestinal products.
Large excipient companies have an advantage in audit readiness, global distribution, regulatory documentation, and continuity planning. Smaller suppliers can compete through flexible batch sizes, regional pricing, and customer-specific specifications.
A buyer’s strongest negotiating leverage exists before qualification. After approval, the incumbent supplier gains leverage because switching can require comparative testing, stability studies, regulatory assessment, and production validation.
What generic launch scenarios exist?
Generic and private-label launch risk is product-specific.
Low-risk scenario
A manufacturer uses dihydroxyaluminum aminoacetate in a long-established formula with no enforceable formulation patent and no exclusivity. Entry can occur after regulatory approval and manufacturing qualification.
Moderate-risk scenario
A product depends on a narrow suspension profile, taste-masking system, or combination ratio. The ingredient is available, but the finished formulation may require substantial development and comparative testing.
High-risk scenario
A branded product claims a proprietary delivery system, treatment method, or combination protected by unexpired patents. The excipient itself does not remove the finished-product patent barrier.
Key Takeaways
- Dihydroxyaluminum aminoacetate is a specialty pharmaceutical raw material with limited publicly measurable standalone revenue.
- Its demand is tied mainly to legacy gastrointestinal and antacid formulations.
- The likely financial trajectory is stable to modestly declining volume, with nominal price support from GMP, testing, and qualification costs.
- Aluminum hydroxide, magnesium hydroxide, and calcium carbonate are the main competitive alternatives.
- Regulatory acceptance is product- and market-specific. FDA inactive-ingredient precedent does not equal universal approval.
- The compound has little standalone Orange Book, Paragraph IV, biosimilar, or composition-of-matter risk.
- The strongest commercial barriers are supplier qualification, manufacturing consistency, elemental-impurity control, and customer switching costs.
- Formulation and method-of-use patents may affect finished products even when the excipient itself is not patent-protected.
- Supplier revenue is likely to depend more on customer retention and regulatory documentation than on significant volume growth.
FAQs about dihydroxyaluminum aminoacetate
Is dihydroxyaluminum aminoacetate the same as aluminum glycinate?
The names are commonly used for the same or closely related aluminum-amino-acid material, but regulatory and supplier documentation should confirm the exact chemical identity, composition, and specification.
Can dihydroxyaluminum aminoacetate be used in an FDA-regulated oral product?
It may be used where the formulation has an appropriate regulatory basis and the material is supported by applicable FDA precedent or product-specific approval. Use as an excipient and use as an active antacid require separate regulatory analysis.
Why is the compound difficult to replace after product approval?
Replacement can change pH, dissolution, suspension behavior, taste, impurity profile, stability, and manufacturing performance. Those changes may require testing, validation, and regulatory review.
Does aluminum aminoacetate have a generic-drug market?
The compound itself is not a generic drug. Generic competition occurs at the level of finished antacid or gastrointestinal products that may contain the compound.
What is the largest financial risk for a supplier?
The largest risk is loss of a qualified customer or product line. Because the market is specialized, discontinuation of one major finished product can affect supplier revenue more than ordinary commodity-price movement.
References
- International Council for Harmonisation. (2019). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org
- U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase
- U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-overview
- U.S. Food and Drug Administration. (n.d.-c). Antacid drug products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. Part 331. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-331
- United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
